Is Venmax Drugs And Pharmaceuticals Ltd (531015) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Venmax Drugs And Pharmaceuticals Ltd is a below average quality company .

Is Venmax Drugs And Pharmaceuticals Ltd (531015) undervalued or overvalued?

The key valuation ratios of Venmax Drugs And Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone .

What is Venmax Drugs And Pharmaceuticals Ltd (531015) share price return in the past 10 years?

Venmax Drugs And Pharmaceuticals Ltd share price has appreciated 23.6% annually (CAGR) over the past ten years.

Is Venmax Drugs And Pharmaceuticals Ltd (531015) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Venmax Drugs And Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Venmax Drugs And Pharmaceuticals Ltd (531015)?

Company share prices are keep on changing according to the market conditions. The current trading price of Venmax Drugs And Pharmaceuticals Ltd (531015) on 30-Apr-2026 16:59:59 at 16:59 is 24.51.

What is the P/E ratio of Venmax Drugs And Pharmaceuticals?

The latest standalone P/E ratio of Venmax Drugs And Pharmaceuticals as of 30-Apr-2026 is 32.63.

What is the P/B ratio of Venmax Drugs And Pharmaceuticals Ltd (531015)?

The latest standalone P/B ratio of Venmax Drugs And Pharmaceuticals Ltd (531015) as of 30-Apr-2026 is 1.71.

What is the 52-week high and low of Venmax Drugs And Pharmaceuticals Ltd (531015)?

The 52-week high of Venmax Drugs And Pharmaceuticals Ltd (531015) is Rs. 36.96 and the 52-week low is Rs. 19.01.

Venmax Drugs And Pharmaceuticals Ltd (531015) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Venmax Drugs And Pharmaceuticals Ltd (531015)
Brand: Venmax Drugs And Pharmaceuticals

Venmax Drugs And Pharmaceuticals Ltd (531015) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Venmax Drugs And Pharmaceuticals Ltd (531015)

BSE: 531015 NSE:

Key Metrics

Market Cap

₹28 Cr.

P/E Ratio

32.63

Price to Book (P/B)

1.71

Price to Sales (P/S)

6.43

EV/EBITDA

33.46

Return on Capital Employed (ROCE)

-0.64%

Current Price

₹24.5

Return on Equity (ROE)

0.00%

Return on Assets (ROA)

-0.40%

Operating Profit Margin

-131.3%

Net Profit Margin

-1.3%

Gross Profit Margin

-1%

Book Value per Share

₹14.3

Sales Growth (YoY)

NA%

Sales Growth (3 Years)

NA%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

N/A%

Net Profit Growth (1 Year)

-116.67%

52-Week Low / High

₹19 / 37

Net Profit Growth (3 Years)

NAN%

Dividend Yield

0.00%

Promoter Holding

13.80%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Stock return of Venmax Drugs And Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 23.6% based on the current price.

Q.1 Revenue growth of Venmax Drugs And Pharmaceuticals Ltd?

Venmax Drugs And Pharmaceuticals Ltd revenue growth is 0% for FY-2025, which is below its 5-year CAGR of 11.5%, indicating slower growth.

Q.1 Which industry/sub-sector does Venmax Drugs And Pharmaceuticals Ltd belong to?

Venmax Drugs And Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Promoter shareholding and pledge status of Venmax Drugs And Pharmaceuticals Ltd?

Promoters hold 13.80% of the Venmax Drugs And Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Venmax Drugs And Pharmaceuticals Ltd vs industry peers?

Venmax Drugs And Pharmaceuticals Ltd revenue CAGR is 11.50%, compared to the industry median CAGR of 8.30%, indicating faster growth and gaining its market share.

DeciZen - make an informed investing decision on Venmax Drugs&Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Venmax Drugs And Pharmaceuticals stock performance

Key Ratios

Is Venmax Drugs And Pharmaceuticals Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-7.3%	-140.9%	0%	0%	0%	0%	0%	0%	0%	-0.6%	-
Value Creation Index ⓘ	-1.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1.9	0.3	0	0.2	0.5	0.2	0	0	0	0.8	4
Sales YoY Gr.	-	-86.5%	-100%	NA	213.3%	-63.8%	-100%	NA	NA	NA	-
Adj EPS ⓘ	-0.3	-1.4	-0.5	-0.5	-0.5	-0.3	3.5	0.4	0.1	-0	0.8
YoY Gr.	-	NA	NA	NA	NA	NA	NA	-87.8%	-72.1%	-116.7%	-
BVPS (₹) ⓘ	0.4	-3.6	-4	-4.5	-5	-5.3	-1.8	-1.4	-1.2	-1.3	14.3
Adj Net Profit ⓘ	-0.1	-0.7	-0.2	-0.2	-0.3	-0.2	1.9	0.2	0.1	-0	1
Cash Flow from Ops. ⓘ	-0.2	-1.1	-0.3	-0.1	-0.3	0.3	1.9	-0	0	-2.3	-
Debt/CF from Ops. ⓘ	-9.2	-1.8	-8	-47.1	-9	8.8	0.2	-113.6	160.1	-0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-9.2%	11.5%	NA	NA
Adj EPS ⓘ	NA	NA	-117.8%	-116.7%
BVPSⓘ	-214.3%	NA	NA	NA
Share Price	23.6%	42.4%	80.3%	-7.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-51.5	89.1	12.2	10.6	11	6	-99.1	-27.3	-9.5	-0.6	11.5
Op. Profit Mgn % ⓘ	-7.1	-237.6	0	-157.8	-53.9	-198.2	0	0	0	-131.3	-4.2
Net Profit Mgn % ⓘ	-7.1	-287.3	0	-156.8	-57.9	-96.8	0	0	0	-1.3	19.7
Debt to Equity ⓘ	8.7	-1	-1	-1	-1	-0.8	-0.4	-0.5	-0.5	-0.1	0
Working Cap Days ⓘ	430	1,303	0	339	219	539	0	0	0	601	992
Cash Conv. Cycle ⓘ	13	93	0	-85	-55	-729	0	0	0	81	658

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	0.8	-
TTM Sales (₹ Cr.)	4.4	-
BVPS (₹) ⓘ	14.3	-
Reserves (₹ Cr.) ⓘ	5	-
P/BV ⓘ	1.71	-
PE ⓘ	32.63	-

From the Market
52 Week Low / High (₹)	19.01 / 36.96
All Time Low / High (₹)	1.10 / 36.96
Market Cap (₹ Cr.)	28.4
Equity (₹ Cr.)	11.6
Face Value (₹)	10
Industry PE ⓘ	43.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Venmax Drugs&Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	1.93	0.26	0	0.15	0.47	0.17	0	0	0	0.81
Operating Expenses ⓘ +	2.07	0.87	0.23	0.39	0.73	0.50	0.13	0.19	0.10	1.87
Manufacturing Costs	0	0	0	0.01	0.01	0	0	0.01	0	0
Material Costs	1.91	0.24	0	0.09	0.32	0.29	0	0	0	0.79
Employee Cost	0.04	0.06	0.05	0.10	0.22	0.06	0.01	0.03	0.02	0.04
Other Costs ⓘ	0.12	0.57	0.18	0.19	0.18	0.14	0.12	0.15	0.08	1.03
Operating Profit ⓘ	-0.14	-0.62	-0.23	-0.24	-0.25	-0.33	-0.13	-0.19	-0.10	-1.06
Operating Profit Margin (%)	-7.1%	-237.0%	-	-157.0%	-53.9%	-198.0%	-	-	-	-131.0%
Other Income ⓘ +	0	0.12	0	0	0	0.18	1.98	0.42	0.20	1.05
Exceptional Items ⓘ	0	-0.84	0	0	0	0	0	0	0	0
Interest ⓘ	0	0	0.01	0	0	0	0	0	0	0
Depreciation ⓘ	0	0	0	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Profit Before Tax ⓘ	-0.14	-1.34	-0.24	-0.24	-0.27	-0.16	1.85	0.23	0.09	-0.01
Tax ⓘ	0	0	0	-0	0.01	0	0	0	0.02	-0
Profit After Tax	-0.14	-1.34	-0.24	-0.24	-0.27	-0.16	1.85	0.23	0.06	-0.01
PAT Margin (%)	-7.1%	-515.0%	-	-156.0%	-57.9%	-96.8%	-	-	-	-1.3%
Adjusted EPS (₹)	-0.3	-2.6	-0.5	-0.5	-0.5	-0.3	3.5	0.4	0.1	-0.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	0.20	-1.87	-2.11	-2.35	-2.62	-2.79	-0.94	-0.71	-0.65	-0.66
Share Capital ⓘ	5.24	5.24	5.24	5.24	5.24	5.24	5.24	5.24	5.24	5.24
Reserves ⓘ	-5.04	-7.11	-7.35	-7.59	-7.86	-8.03	-6.18	-5.95	-5.89	-5.90
Debt +	1.72	1.85	2.04	2.24	2.52	2.33	0.35	0.35	0.35	0.05
Long Term Debt	1.72	0	0	0	0	0	0	0	0	0
Short Term Debt	0	1.85	2.04	2.24	2.52	2.33	0.35	0.35	0.35	0.05
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.57	0.08	0.06	0.31	0.40	0.46	0.47	0.33	0.10	0.63
Others Liabilities ⓘ	-0.74	0.08	0.09	0.13	0.16	0.30	0.33	0.25	0.28	5.15
Total Liabilities ⓘ	1.75	0.14	0.07	0.33	0.46	0.31	0.21	0.21	0.08	5.17
Fixed Assets
Net Fixed Assets ⓘ +	0	0	0	0.11	0.10	0.09	0.08	0.07	0.07	0.04
Gross Block	0	0	0	0.12	0.12	0.12	0.09	0.07	0.07	0.07
Accumulated Depreciation	0	0	0	0.01	0.02	0.03	0.01	0	0.01	0.03
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0.01	0	0	0	0	0	0	0	0	0
Inventories	0	0	0	0.11	0.22	0	0	0	0	0.06
Trade Receivables	0.68	0	0	0	0.04	0.04	0.04	0.04	0	0.95
Cash Equivalents ⓘ	0.03	0	0	0	0	0.08	0	0	0	2.48
Others Assets ⓘ	1.03	0.14	0.07	0.11	0.10	0.11	0.10	0.10	0.01	1.64
Total Assets ⓘ	1.75	0.14	0.07	0.33	0.46	0.31	0.21	0.21	0.08	5.17

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0.19	-1.06	-0.26	-0.05	-0.28	0.26	1.91	-0	0	-2.29
PBT ⓘ	-0.14	-1.34	-0.24	-0.24	-0.27	-0.16	1.85	0.23	0.09	-0.01
Adjustment ⓘ	0	-0.09	0	0	0.01	0.01	0.01	0.01	0.01	0.03
Changes in Working Capital ⓘ	-0.05	0.37	-0.01	0.19	-0.03	0.42	0.05	-0.24	-0.07	-2.3
Tax Paid ⓘ	0	0	0	0	0	0	0	0	-0.02	0
Cash Flow From Investing Activity ⓘ +	0	0.01	0	-0.11	0	0	0	0	0	0
Capex	0	0.01	0	-0.12	0	0	0	0	0	0
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	0.22	1.02	0.26	0.16	0.28	-0.19	-1.98	0	0	4.77
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	5.07
Net Proceeds from Borrowing ⓘ	0	0.13	0.19	0.16	0.28	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.22	0.89	0.07	0	0	-0.19	-1.98	0	0	-0.30
Net Cash Flow ⓘ	0.03	-0.03	0	0	-0	0.07	-0.07	0	0	2.48

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-51.49	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ROCE (%)	-7.34	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover Ratio	0.84	0.27	0	0.75	1.2	0.44	0	0	0	0.31
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	N/A	1.03	-0	0	N/A
Working Capital Days
Receivable Days	78	0	0	5.40	15.50	80.70	0	0	0	430.70
Inventory Days	0	0	0	254.20	124.10	0	0	0	0	26
Payable Days	211.10	484.50	0	733.70	410.40	537.40	0	0	0	168.20

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Venmax Drugs And Pharmaceuticals Ltd FAQs

The current trading price of Venmax Drugs&Pharma on 30-Apr-2026 16:59 is ₹24.51.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Apr-2026 the market cap of Venmax Drugs&Pharma stood at ₹28.39 Cr

The latest P/E ratio of Venmax Drugs&Pharma as of 29-Apr-2026 is 32.63.

The latest P/B ratio of Venmax Drugs&Pharma as of 29-Apr-2026 is 1.71.

The 52-week high of Venmax Drugs&Pharma is ₹36.96 and the 52-week low is ₹19.01.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Venmax Drugs&Pharma is ₹4.41 ( Cr.) .

About Venmax Drugs And Pharmaceuticals Ltd

Venmax Drugs and Pharmaceuticals is a public limited company incorporated under Companies Act, 1956 and domiciled in India. The company was initially incorporated as private limited company under the name and style of ‘Yenkay Medico Private Limited’, on September 28, 1998. The company thereafter changed its name to ‘Yenkey Drugs & Pharmaceuticals Private Limited’ on January 18, 1995. The company has become a public limited company on February 3, 1995 with ‘Yenkey Drugs & Pharmaceuticals Ltd’. Finally, the company has changed its name to ‘Venmax Drugs & Pharmaceuticals Ltd’ on April 13, 2009.

The company is engaged in the business of pharmaceutical products, drug intermediates, and Active Pharmaceutical Ingredients (APIs). It is currently developing oncology products in its R&D division. The company is planning to establish a cGMP-compliant manufacturing unit in the Pharma Cluster at Hyderabad to meet export demand.

Business area of the company

Venmax Drugs and Pharmaceuticals is engaged in the business of pharmaceutical products, drug intermediates, and active pharmaceutical ingredients.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Venmax Drugs And Pharmaceuticals Ltd (531015) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Venmax Drugs&Pharma Share Price